Search company, investor...

AdvanSource Biomaterials Corporation

advbiomaterials.com

Founded Year

1993

Stage

Acq - P2P | Acquired

Total Raised

$4.9M

Valuation

$0000 

About AdvanSource Biomaterials Corporation

AdvanSource Biomaterials Corporation is a Healthcare/Medical Devices & Equipment company based in Wilmington, Massachusetts. AdvanSource Biomaterials Corporation's investors include Iroquois Capital, Gryphon, Meadowbrook Capital Management, Atoll Asset Management and Heights Capital Management. On February 3rd, 2020, AdvanSource Biomaterials Corporation was acquired by Mitsubishi Chemical for 7.25M.

Headquarters Location

229 Andover Street

Wilmington, Massachusetts, 01887,

United States

978-657-0075

Missing: AdvanSource Biomaterials Corporation's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: AdvanSource Biomaterials Corporation's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing AdvanSource Biomaterials Corporation

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

AdvanSource Biomaterials Corporation is included in 1 Expert Collection, including CB Insights IEM Industry Leaders.

C

CB Insights IEM Industry Leaders

1,318 items

Industry Leaders list for industrials, energy, and mobility (broken down by individual sheets)

AdvanSource Biomaterials Corporation Patents

AdvanSource Biomaterials Corporation has filed 3 patents.

The 3 most popular patent topics include:

  • Implants (medicine)
  • Medical equipment
  • Medical technology
patents chart

Application Date

Grant Date

Title

Related Topics

Status

10/13/2010

8/14/2012

Thermoplastics, Copolymers, Polymers, Elastomers, Polymer chemistry

Grant

Application Date

10/13/2010

Grant Date

8/14/2012

Title

Related Topics

Thermoplastics, Copolymers, Polymers, Elastomers, Polymer chemistry

Status

Grant

Latest AdvanSource Biomaterials Corporation News

13:00 EDT Biomaterials Global Market Report 2022

Nov 1, 2022

" report has been added to ResearchAndMarkets.com's offering. This report provides strategists, marketers and senior management with the critical information they need to assess the global biomaterials market. The global biomaterials market is expected to grow from $91.08 billion in 2021 to $103.18 billion in 2022 at a compound annual growth rate (CAGR) of 13.28%. The biomaterials market is expected to reach $180.36 billion in 2026 at a compound annual growth rate (CAGR) of 15.03%. Reasons to Purchase Gain a truly global perspective with the most comprehensive report available on this market covering 12+ geographies. Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates. Create regional and country strategies on the basis of local data and analysis. Identify growth segments for investment. Outperform competitors using forecast data and the drivers and trends shaping the market. Understand customers based on the latest market research findings. Benchmark performance against key competitors. Utilize the relationships between key data sets for superior strategizing. Suitable for supporting your internal and external presentations with reliable high quality data and analysis Major players in the biomaterials market are Carpenter Technology Corporation, Corbion NV, Evonik Industries, Royal DSM, Berkeley Advanced Biomaterials, BASF SE, Zimmer Biomet, Johnson and Johnson, Invibio, Medtronic, Organogenesis Holdings Inc, Stryker, Wright Medical Group NV, 3M Healthcare, AdvanSource Biomaterials Corporation, Baxter, Covestro, Cam Bioceramics BV, Celanese Corporation, CoorsTek Inc, CeramTec, Victrex plc and Collagen Matrix Inc. The biomaterials market consists of sales of biomaterials by entities (organizations, sole traders, and partnerships) that refer to natural or synthetic materials used in medical applications to support, enhance, or replace damaged tissue or a biological function. Biomaterials are manmade substances that can be utilized to support tissues or structures in the body. The main types of biomaterials are metallic biomaterial, polymeric biomaterials, natural biomaterials and ceramics. The metallic biomaterial are a stainless steels, titanium alloys, and cobalt alloys used to provide internal support to biological tissues. The metallic biomaterials are manmade systems that are utilized in joint replacements, dental implants, orthopedic fixations, and stents to offer internal support to biological tissues. Biomaterials have a wide application in cardiovascular, orthopedic, ophthalmology, dental, plastic surgery, wound healing, tissue engineering and neurological/central nervous system and are used in hospitals and clinics, ambulatory surgical centers and other end users. North America was the largest region in the biomaterials market in 2021. The regions covered in the biomaterials market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The biomaterials market research report is one of a series of new reports that provides biomaterials market statistics, including biomaterials industry global market size, regional shares, competitors with a biomaterials market share, detailed biomaterials market segments, market trends and opportunities, and any further data you may need to thrive in the biomaterials industry. This biomaterials market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The rising incidence of cardiovascular diseases is driving the growth of the biomaterials market. Cardiovascular disorders are caused by high blood pressure, smoking, high cholesterol, inactivity, and other factors. The increase in the prevalence of cardiovascular disorders is mainly due to noncontagious diseases like diabetes, chronic respiratory illness, and heart attacks due to hypertension. Biomaterials such as heart valves, cardiopulmonary bypass system, stents, vascular grafts, complete artificial heart, and pacemakers are used as a healing mechanism for damaged and diseased heart tissue. The strategic partnership is a key trend gaining popularity in the biomaterials market. Key companies are focusing on partnerships to develop new implants and combination devices based on biomaterials by leveraging each other's expertise, technology, and resources. These partnerships are also focused on enhancing the adoption of biomaterials. Such partnerships enable companies to gain a competitive edge in the market and increase revenue In January 2021, Evonik Industries AG, a German specialty chemicals company acquired the LACTEL business of biodegradable polymers from DURECT Corporation for $15 million. With this acquisition, Evonik aims to expand in fast-growing markets such as biomaterials for tissue engineering, advanced drug delivery, and the 3D printing of implantable medical devices. DURECT Corporation is a US-based specialty pharmaceutical company. The countries covered in the biomaterials market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA. Key Topics Covered:

AdvanSource Biomaterials Corporation Frequently Asked Questions (FAQ)

  • When was AdvanSource Biomaterials Corporation founded?

    AdvanSource Biomaterials Corporation was founded in 1993.

  • Where is AdvanSource Biomaterials Corporation's headquarters?

    AdvanSource Biomaterials Corporation's headquarters is located at 229 Andover Street, Wilmington.

  • What is AdvanSource Biomaterials Corporation's latest funding round?

    AdvanSource Biomaterials Corporation's latest funding round is Acq - P2P.

  • How much did AdvanSource Biomaterials Corporation raise?

    AdvanSource Biomaterials Corporation raised a total of $4.9M.

  • Who are the investors of AdvanSource Biomaterials Corporation?

    Investors of AdvanSource Biomaterials Corporation include Mitsubishi Chemical Holdings, Iroquois Capital Group, Meadowbrook Capital Management, Gryphon Investors, Heights Capital Management and 4 more.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.